The aim of the study was to derive and validate a novel risk score for early right-sided heart failure (RHF) after left ventricular assist device implantation.
C
ontinuous-flow left ventricular (LV) assist devices (LVADs) are increasingly used in patients with endstage heart failure (HF) as a bridge to transplantation, a bridge to candidacy, or destination therapy (DT). The 1-year survival reported for patients treated with continuous-flow LVAD was ≈80% and 73% in the IN-TERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) and EUROMACS (European Registry for Patients with Mechanical Circulatory Support), respectively. 1, 2 Early post-LVAD mortality is due partly to the development of right-sided HF (RHF) in the early post-LVAD phase. 3 The pathophysiology of RHF, however, is not well known. 4, 5 Post-LVAD RHF has been reported to be between 4% and 50%, [6] [7] [8] [9] [10] and RHF-associated 6-month mortality was seen in up to 29% of patients receiving an LVAD. 11 Moreover, RHF has a greater impact in patients who receive LVAD as DT, for whom there is no opportunity for bailout with heart transplantation.
Management of RHF depends primarily on the timing and severity of the condition. Patients with severe preoperative RHF are usually considered for biventricular support. In primary LVAD operations, post-LVAD patients with RHF often require prolonged inotropic support, nitric oxide (NO) ventilation, prolonged intensive care unit (ICU) stay, or temporarily a right ventricular (RV) assist device.
Prediction and early recognition of RHF could help in timely intervention and thus improvement of patients' outcome. Several prediction scores of RHF in patients with LVAD have been proposed. 9, [11] [12] [13] Those prediction scores have mostly been based on earlier-generation LVADs and were derived from rather small populations or heterogeneous LVADs.
The objective of this study was to develop and validate a new simple score to predict early post-LVAD RHF in a large population with continuous-flow LVADs from the EUROMACS Registry.
METHODS

The EUROMACS Registry
The EUROMACS is a registry of the European Association for Cardio-Thoracic Surgery. The registry gathers data for scientific analyses, aimed at improving care of patients with end-stage HF who require mechanical circulatory support. 2 All relevant clinical, echocardiographic, hemodynamic, and laboratory parameters were prospectively collected by participating sites in the EUROMACS Registry and entered into an electronic database (see Appendix I in the online-only Data Supplement for the list of the EUROMACS sites and investigators [alphabetic according to country]). The EUROMACS Registry began officially in January 1, 2011, but sites were also allowed to collect data retrospectively from patients who were already implanted before that date. A protocol for data collection and data entry, including all relevant data for the registry, was provided to all participating centers before data entry was allowed. Details of the registry and data collection are described elsewhere. 2 This study was approved by the institutional review committee of all respective participating centers, and all subjects gave informed consent.
Study Design
The present study was approved by the EUROMACS Committee. All patients (n=3897) undergoing LVAD implantation between January 2006 and May 2017 were identified. We excluded patients <18 years of age (n=171) and patients with primary devices (total artificial heart, single-ventricle assist device) other than LVAD (n=97). Devices other than mainstream (n=641) were also excluded ( Figure 1 ).
Study Outcome
The primary outcome was early (<30 days) severe postoperative RHF, defined as receiving short-or long-term right-sided
Clinical Perspective
What Is New?
• This project provides a novel and simple risk score for right-sided heart failure in adults undergoing left ventricular assist device implantation with current mainstream devices. • Using 2988 adults (age >18 years) who underwent continuous-flow left ventricular assist device implantation across the European Union in the largest EU Registry of mechanical circulatory support devices, we derived and validated a right-sided heart failure prediction model that outperformed several published scores and well-known hemodynamic and echocardiographic individual markers of right-sided heart failure.
• The right-sided heart failure prediction model included the following risk factors: need of ≥3 inotropic agents, Interagency Registry for Mechanically Assisted Circulatory Support class 1 through 3, severe right ventricular dysfunction on semiquantitative echocardiography, ratio of right atrial to pulmonary capillary wedge pressure >0.54, and hemoglobin ≤10 g/dL.
What Are the Clinical Implications?
• Our findings offer a step toward improving prediction of the risk of right-sided heart failure among patients undergoing left ventricular assist device implantation.
• This score may help to target future optimal strategies aiming at early and intensive right-sided heart failure management for the highest-risk subgroups of the left ventricular assist device population.
• Future studies should determine whether early right ventricular assist device implantation or intensive right-sided heart failure medication can improve survival and reduce intensive care unit stay among left ventricular assist device candidates at high risk for right-sided heart failure.
Soliman et al Prediction Model for Right-Sided Heart Failure After LVAD ORIGINAL RESEARCH ARTICLE circulatory support, continuous inotropic support for ≥14 days, or NO ventilation for ≥48 hours. 14 The secondary outcome was all-cause mortality and length of stay in the ICU. We used a hierarchy selection of the components of RHF definition in which the need for RV assist device has the strongest weight, the prolonged use of inotropes comes next, and the use of inhaled NO comes last. Of note, only a small minority were defined on the basis of the last outcome component.
Potential Predictors of RHF
We examined 82 potential preoperative predictors and cardiopulmonary bypass (CPB) time for the association with RHF. Preoperative clinical data included age, sex, body surface area, body mass index, ethnic origin and blood group type, HF etiology, New York Heart Association functional class, and INTERMACS class. 15 Comorbidity factors included diabetes mellitus, history of neurological events, carotid artery disease, history of cardiac arrest, use of mechanical ventilation, use of feeding tube, implantable cardioverter-defibrillator, history of major myocardial infarction, previous cardiac surgery, renal dialysis, ultrafiltration, and positive blood culture. Furthermore, LVAD strategies such as DT, use of an intraaortic balloon pump, and use of extracorporeal membrane oxygenator were also included.
The preoperative use of HF medication included individual medications such as milrinone, dobutamine, dopamine, levosimendan, vasopressors, norepinephrine, and epinephrine, as well as the use of ≥3 intravenous inotropes. Amiodarone, angiotensin-converting enzyme inhibitors, β-blockers, aldosterone antagonists, loop diuretics, and anticoagulants were also examined.
Preoperative echocardiographic parameters were recorded and analyzed in accordance with published guidelines, 16, 17 including tricuspid annular plane systolic excursion, RV dysfunction on visual score, LV diastolic and systolic dimensions and volumes, LV ejection fraction, and mitral, aortic, and tricuspid valvular regurgitation. Median duration of echocardiographic data collection before LVAD surgery was 6 days. Severity of valvular regurgitation was graded as none, trivial, mild, moderate, or severe according to published guidelines. 18, 19 Hemodynamic predictors included cardiac rhythm, heart rate, systolic and diastolic blood pressures, and Swan-Ganz recordings. The Swan-Ganz recordings included systolic, diastolic, and mean pulmonary artery (PA) pressure; right atrial (RA) pressure; transpulmonary gradient; pulmonary vascular resistance; pulmonary capillary wedge pressure (PCWP); pulmonary and systemic vascular resistance; stroke index; and cardiac index. The transpulmonary gradient was calculated as the difference between the PA mean pressure and PCWP, which has a normal value of ≤12 mm Hg. Pulmonary vascular resistance is calculated as transpulmonary gradient divided by cardiac output, which has a normal value of <3 Wood units (or 240 dynes·s·cm −5 ). The ratio of RA to PCWP and the PA pulsatility index 20 were also calculated. The RV systolic work index was calculated as follows: RV stroke volume index×(mean PA pressure−central venous pressure)×0.0136 expressed in grams per square meter per beat. The factor 0.0136 was used to covert pressure (millimeters of mercury) into work (grams per square meter). Normal values are 5 to 10 g/m 2 per beat. Candidate laboratory variables included serum sodium and potassium levels; renal function parameters, including blood urea nitrogen; serum creatinine levels; and liver function parameters, including alanine transaminase, aspartate transaminase, lactate dehydrogenase, total bilirubin, and serum albumin levels. In addition, white blood count, platelets count, hemoglobin level, and serum C-reactive protein were evaluated.
Statistical Analysis
Patient characteristics are described as means (SD) or medians (interquartile range [IQR]) for continuous variables and frequency (percentage) for categorical variables. Differences between patient groups were evaluated for continuous variables by the Student t tests (gaussian distribution) or nonparametric Mann-Whitney U tests (nongaussian distribution) and for categorical variables with the χ 2 test. Univariate logistic regression analysis was applied to relate a broad range of preoperative parameters to the study outcome, including demographics, clinical values, comorbidities, medications, and echocardiographic, hemodynamic, and laboratory parameters. Variables with a value of P<0.10 entered the multivariate stage, and a logistic regression model was constructed to predict early post-LVAD RHF, applying the stepwise forward method, with a value of P=0.05 a modelentry criterion. All variables were checked for multicollinearity assumption using correlations, tolerance, and variable inflation factor to avoid redundancy in the prediction model. Casewise diagnostics were done, as well as a check for the Mahalonobis and Cook distances for outliers. Outliers outside 3 SD were omitted.
Dichotomization of all relevant continuous variables was performed at the 25th percentile (systolic blood pressure, diastolic blood pressure, cardiac index, PA pulsatility index, RV stroke work index, serum albumin, serum hemoglobin, and platelets), at the 50th percentile (body surface area, tricuspid annular plane systolic excursion, LV end-diastolic diameter, LV All continuous values are presented in mean±SD unless stated otherwise or presented as median (IQR). AST indicates serum aspartate transaminase; IABP, intra-aortic balloon pump; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support (for INTERMACS classes, see text for details); LV, left ventricular; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PAP, pulmonary artery pressure; PAPI, pulmonary artery pulsatility index; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RA, right atrial; RV, right ventricular; RVSWI, right ventricular stroke work index; TAPSE, tricuspid annular plane systolic excursion; and VA-ECMO, veno-arterial extracorporeal membrane oxygenator.
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end-diastolic volume, systolic PA pressure, diastolic PA pressure, transpulmonary gradient, RA pressure, systemic vascular resistance, and RA/PCWP ratio), or at the 75th percentile (heart rate, CPB time, serum creatinine, serum alanine transaminase, serum aspartate transaminase, lactate dehydrogenase, total bilirubin, white cell count, and serum C-reactive protein). Dichotomization was based mainly on clinical relevance such as using the 25th percentile for a variable with a known association of its lower value and worse outcome and vice versa. In some cases such as the RA/PCWP ratio, we used the receiver-operating characteristic (ROC) curve area under the curve (AUC) analysis to calculate the best cutoff point for its association with RHF. The relative magnitude of the model regression coefficients from statistically significant variables in the final multivariable model was used to calculate an individual patient's risk score for the development of post-LVAD RHF. The model discrimination abilities were evaluated by the c index of the final multivariate model. ROC curve analysis of the EUROMACS-RHF risk score was compared with published risk scores and with individual known markers of RHF. Finally, we validated the risk model in the validation cohort. The optimal cutoff value for the EUROMACS-RHF risk score was calculated through the ROC curve and the respective Youden index.
We handled the missing data by performing multiple imputations of all relevant parameters in the entire population. SPSS version 24 was used for multiple imputations using the automated function. After analyzing the patterns of missing values in the data set, we used the built-in automatic method that perform imputations based on data scanning. The automatic method scans the data and uses the monotone method if the data show a monotone pattern of missing values; otherwise, fully conditional specification is used. A 50% limit for the missing data was set to exclude variables with excessive missing data. No relevant parameter had >10% missing data. Furthermore, the vast majority of variables that were included in the final multivariable regression model had <5% missing data.
The incidence rate of post-LVAD RHF was calculated over the follow-up period. We plotted Kaplan-Meier curves for the occurrence of up to 2-year all-cause mortality according to the presence or absence of post-LVAD RHF and stratified by the EUROMACS-RHF risk score categories. The log-rank test was used to examine time to mortality differences in the Kaplan-Meier analyses. A 2-tailed value of P<0.05 was considered statistically significant, and all statistics were undertaken with SPSS statistics version 24 (IBM Corp, Armonk, NY) and the R-statistical package.
RESULTS
Patient Population
The final study population comprised 2988 patients with a mean age of 53±13 years and 523 women (18%). The majority were white (68%, n=2022). The main type of HF was nonischemic (66%, n=1985). The main indication for LVAD was bridge to candidacy (37%, n=1102), followed by bridge to transplantation (24.5%, n=731). HeartWare HVAD was the most used LVAD brand (50.5%, n=1509), followed by HeartMate II (40.3%, n=1204), and the minority received HeartMate 3 (8%, n=240).
Derivation and Validation Cohorts
The final study patients were randomly divided into derivation (67%, n=2000) and validation (33%, n=988) cohorts. Both cohorts were well matched in key baseline and operative characteristics (Tables 1 and 2 Figure I in the online-only Data Supplement.
Logistic Regression Analysis for Early Post-LVAD RHF
Exploratory univariate logistic regression analysis for early post-LVAD RHF yielded 58 potential covariates (P<10) of 83 tested variables, which are listed in Tables 3 and 4 , as clinical, medication, laboratory, echocardiographic, hemodynamic, and operative covariates (Table 5) . Covariates were eliminated because of reasons mentioned above such as collinearity, resulting in 21 variables in the multivariable model. Significant predictors of early post-LVAD RHF in the derivation cohort included INTERMACS class, need for multiple intravenous inotropes, severe RV dysfunction, RA/PCWP ratio, and hemoglobin. The final model has a c index of 0.70 in the derivation cohort. Patients in INTERMACS class 1 through 3 had a 27% risk of RHF versus 12% risk for those in INTERMACS class 4 through 7 (P<0.001). Additionally, patients on ≥3 inotropic agents in the preoperative period had 42% risk of RHF versus 22% risk for those on ≤2 inotropic agents (P<0.001). In terms of semiquantitative echocardiographic assessment, patients with severe RV dysfunction on visual score had 50% risk of RHF versus 23% for those with better RV function. Furthermore, patients with an RA/PCWP ratio >0.54 had 27.1% risk of RHF versus 16.1% for those with lower ratio (P<0.001). Finally, patients with hemoglobin ≤10 g/dL had 35% risk of RHF versus 23% risk for those with hemoglobin >10 g/dL (P<0.001).
EUROMACS-RHF Risk Score
With the use of the relative magnitude of the coefficient of regression in the multivariable model in the ALT indicates alanine transaminase; AST, serum aspartate transaminase; BUN, blood urea nitrogen; CI, confidence interval; HCO, bicarbonates; LDH, lactate dehydrogenase; LV, left ventricular; OR, odds ratio; PAP, pulmonary artery pressure; PAPI, pulmonary artery pulsatility index; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RA, right atrial; RV, right ventricular; RVSWI, right ventricular stroke work index; SVR, systemic vascular resistance; TAPSE, tricuspid annular plane systolic excursion; TPG, transpulmonary gradient; and WBC, white blood cell.
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derivation cohort, points were assigned to the 5 covariates (Table 6 ). Values were rounded to the nearest integer to simplify the calculation of the composite risk score in routine clinical practice. A total 9.5-point score was generated.
Predictive Power of the EUROMACS-RHF Risk Score in the Derivation Cohort
The mean score in the derivation cohort was 2.7±1.9, ranging from 0 to 9.5 ( Figure 2A) . Likewise, data on the operative EUROMACS-RHF risk score are shown in Figure 2B . The predicted rate of RHF was significantly (P for linear trend <0.001) increased from 11% for a score of 0 to 2 to 43.1% for a score of >4 ( Figure 3A) . Sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, positive predictive value, and negative predictive value according to the EUROMACS-RHF risk score are presented in Table I in the online-only Data Supplement, and those of the operative EUROMACS-RHF risk score are presented in Table II in the online-only Data Supplement.
Validation of the EUROMACS-RHF Risk Sore
The mean score in the validation cohort was 2.6±2.0, ranging from 0 to 8.5 ( Figure 2A ). The predicted rate of RHF was similar and significantly (P<0.001 for linear trend) increased from 12.5% for a score of 0 to Examples of risk score calculation using the model presented in Table 6 .
The following example illustrates the use of Table 6 to calculate the European Registry for Patients with Mechanical Circulatory Support (EUROMACS) RHF risk score of early postoperative RHF after LVAD implantation in individual patients:
Consider a patient who was referred to left ventricular assist device implantation who has INTERMACS class 3, has severe RV dysfunction on echocardiography, has an RA/PCWP ratio of 0.55 on Swan-Ganz catheter, is on 3 inotropic support, and has a hemoglobin of 10 g/dL. Using the EUROMACS-RHF risk score of RHF model coefficients in Table 6 , this patient's preoperative risk score for RHF is the highest because he scored all points (2+1+2.5+2+2=9.5) according to the prediction model. Furthermore, if this patient had CPB time >100 min, this patient's postoperative risk score for RHF with a similar formula will be 8.5 points.
*Semiquantitative assessment of RV systolic function on echocardiography. (Table 7) . AUC was similar for the EUROMACS-RHF and modified postoperative EUROMACS-RHF scores (P=0.41). ROC curve comparison with other individual known hemodynamic and echocardiographic markers of RV failure demonstrated the highest AUC for the EUROMACS-RHF score (all P<0.001).
EUROMACS-RHF Risk Score and All-Cause Mortality
Cumulative survival in the postoperative 24 months was higher in patients without RHF at the 6-month (79% versus 61%), 12-month (71% versus 53%), 18-month (65% versus 49%), and 24-month (58% versus 45%) follow-up compared with patients with RHF (log-rank test, P<0.001; Figure 4A ). Likewise, cumulative survival in the postoperative 24 months was at the 6-month (80% versus 66% versus 56%), 12-month (73% versus 60% versus 48%), 18-month (66% versus 54% versus 46%), and 24-month (61% versus 46% versus 43%) follow-up patients with low, intermediate, and high EUROMACS-RHF risk score, respectively (log-rank test, P<0.001; Figure 4B ). Multiorgan failure and sepsis were the most frequent primary causes of death, in particular in patients with RHF. Other common causes of death were cerebrovascular accidents, bleeding, and cardiopulmonary failure ( Figure 5 ). Multiorgan failure was seen in 50% of patients who died with sepsis as the primary cause of death. 
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EUROMACS-RHF Risk Score and ICU Stay Duration
Median ICU stay was 7 days (IQR, 4-15 days) versus 24 days (IQR, 14-38 days) in patients without versus with RHF (P<0.001). Likewise, the ICU stay was linearly increased from 6 days (IQR, 4-13 days) versus 13 days (IQR, 6-25 days) versus 19 days (IQR, 9-31 days) in the EU-ROMACS-RHF score low, intermediate, and high risk category, respectively (P<0.001 for trend; Figure 6A and 6B).
Subgroup Analysis
We performed subgroup analysis to test the predictive value of the EUROMACS-RHF risk score in patient populations treated with different LVADs. The incidence of RHF was 15.5% versus 24.1% versus 24.9% for patients treated with HeartMate II, HeartWare, and HeartMate 3, respectively (P<0.001 for trend; Table III in the online-only Data Supplement). In the derivation cohort, the AUC of the EUROMACS-RHF risk score was 0.75, 0.66, and 0.60 in the HeartMate II, HeartWare, and HeartMate 3 populations, respectively (Table IV in the  online-only Data Supplement) . Sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, positive predictive value, and negative predictive value according to the EUROMACS-RHF risk score in the device brand subgroups are presented on Tables V-VII in the online-only Data Supplement.
DISCUSSION
This study is a multicenter study that includes the largest European population of patients who received currently used continuous-flow LVADs, evaluating the risk for RHF. Early severe RHF occurs in one fifth of patients with LVAD in this study and is associated with high mortality, up to 29% in some series. 11 We developed and validated a novel EUROMACS-RHF risk score using a simple 5-item scoring system for the prediction of early RHF after continuous-flow LVAD implantation. 
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RHF is an important and frequent complication in the early postoperative period after LVAD implantation. 3 In prior studies, rates of post-LVAD RHF have ranged between 4% and 50%. [6] [7] [8] [9] [10] This wide range of reported RHF incidence is due partly to the lack of a universal definition of post-LVAD RHF across the literature. In primary LVAD implantation, severe RHF requires either mechanical RV support via RV assist device or extracorporeal membrane oxygenator, pharmacological support via the use of continuous intravenous inotropic support, or pulmonary vasodilators such as inhaled NO. Those 3 components are used in the RHF definition in this study, which is in line with the INTERMACS definition of severe RHF. 14 Risk stratification of patients undergoing LVAD implantation is important to identify candidates for RV support, to provide timely pharmacological intervention, and thus to improve patients' outcome. This could be important in the decision process, preoperative preparation, and timing of surgery. This should be reflected also in the informed consent of the patients and the family, especially in patients receiving DT in whom there is no opportunity for bailout with heart transplantation. Few risk-scoring systems have been described to predict post-LVAD RHF. However, those studies are limited by small sample size, single centers, and the heterogeneous nature of LVADs. Kormos et al 11 and Atluri et al 21 investigated multivariate predictors of RHF in 484 and 167 patients, respectively, who received continuous-flow LVAD. However, the studies included only HeartMate II devices, disregarding other currently used mainstream LVADs such as HeartWare or the new HeartMate 3. In our study, the EUROMACS-RHF risk score was derived from a population of 2000 patients treated with mainstream LVADs.
Risk Score Components
The EUROMACS-RHF risk score is composed of severe RV dysfunction (2 points), ratio of RA/PCWP ≥0.54 (2 points), advanced INTERMACS class 1 through 3 (2 points), need for ≥3 intravenous inotropes (2.5 points), and hemoglobin ≤10 g/dL (1 point).
Because of the multifactorial nature of RHF after LVAD, 4, 5 83 parameters of clinical relevance are examined in this study for possible association with early post-LVAD RHF.
Patients with preoperative severe RV dysfunction on echocardiography have an ≈2-fold increase in the incidence of evident RHF in the early post-LVAD period compared with those without severe RV dysfunction. Echocardiographic assessment of RV function is readily available to assess RV contractility at bedside. Of note, there is a potential high variability in visual scoring of RV function on a scale from normal to severe; therefore, a quantitative marker such as RV fractional area change or the recently introduced iRotate echocardiography 22 can accurately quantify RV function. Nevertheless, visual assessment of a severe RV dysfunction on echocardiography in daily practice is, in our expert opinion, simple but robust.
Likewise, an elevated RA pressure in relation to pulmonary capillary wedge pressure shows a similar association with clinically evident early post-LVAD RHF. On the one hand, high RA pressure is a sign of RV failure; on the other hand, it could be a sign of volume overload. Aggressive diuresis, usually with inotropic support, and sometimes ultrafiltration, in case of ineffective diuresis, should be tried in patients with volume overload to achieve optimal euvolemic state.
In the EUROMACS database, as well as in other published data, most patients who are receiving an LVAD have some degree of RV dysfunction. In this study, 88% of patients have mild or more impairment of RV systolic function. However, RV dysfunction could remain silent as a result of a limited RV preload. RV preload has to increase immediately after LVAD to match increased LVAD workload. Furthermore, LV unloading tends to cause a leftward shift of the interventricular septum, therefore compromising effective RV contractility and aggravating the already impaired RV systolic function. The interventricular septum contributes to at least one third of the RV contractility. 23 Therefore, it is important to optimize LVAD flow to prevent excessive LV suction to avoid a vicious circle of RV function impairment. The preoperative score includes need of ≥3 inotropic agents, Interagency Registry for Mechanically Assisted Circulatory Support class 1 through 3, severe RV dysfunction on semiquantitative echocardiography, RA/pulmonary capillary wedge pressure ratio >0.54, and hemoglobin ≤10 g/dL.
†The modified postoperative score includes cardiopulmonary bypass time >100 minutes and the 5 preoperative components of the EUROMACS-RHF risk score.
The need for multiple inotropes in the preoperative period in this study was seen in 12% of patients and is associated with an ≈2-fold higher risk of RHF than in patients with ≤2 inotropes. The use of multiple inotropes has the greatest weight in predicting post-LVAD RHF among all 5 predictors. This might reflect, in fact, the biventricular origin of hemodynamic instability. Despite the dire need for inotropic support in those patients, excess or prolonged use of intravenous inotropic agents could have a detrimental effect on the myocardial energetics and metabolism. 24 In this study, an average of 1.5 inotropes were used per patient. Moreover, dobutamine was the most (53%) used inotropic agent ( Figure III in the onlineonly Data Supplement). On the other hand, 12% of patients received levosimendan. Levosimendan is currently available in the European Union and various countries but remains investigational in the United States. 25 Levosimendan could prevents the development of RHF and improves contractility in established pressure overload-induced RV failure in the preclinical setting. 26 However, the short-and long-term outcomes of those inotropic agents have not been demonstrated in randomized clinical trials. Further studies are needed to test their role in early intensive management of RHF. As a potential example, a randomized study could be designed to test a temporary RV circulatory support in patients who are on or require >2 inotropes before LVAD implantation. In this proposed trial, patients could be randomized to an early temporary mechanical circulatory support or to escalating the number or doses of inotropic or vasopressor support.
An advanced INTERMACS score is found in this study to be associated with an ≈5-fold increase in the incidence of evident RHF in the early post-LVAD period compared with those with less advanced INTERMACS class before LVAD. This finding is in line with published data from the INTER-MACS database. 27 We categorized patients according to 3 ) and a second group including "frequent flyers" (class 4) and less sick (class 5 through 7) patients. 28 The first group represents sicker and decompensating patients who suffer severe hemodynamic derangement, threatening secondary organ (renal, hepatic) failure, compared with ambulatory, less sick, or relatively stable patients in the second group.
Finally, anemia as demonstrated with hemoglobin ≤10 g/dL was associated with 1.5-fold increase in post-LVAD RHF. Anemia is found in about one third of patients with chronic HF. The most common causes are chronic renal failure and iron deficiency. It could be speculated that anemia could play a role in triggering RHF in the setting of already vulnerable RV, and multiple blood transfusions in the early postoperative period could play a role in the pathophysiology of RHF in those patients. Blood transfusion-associated circulatory overload has been associated with an increased risk of RHF. 29, 30 Furthermore, the already vulnerable RV is very likely to be challenged by borderline perfusion and thus impaired oxygen delivery resulting from anemia. On the other hand, anemia might reflect the severity of the underlying multiorgan failure. Impaired nutrition, malabsorption (resulting from congestion and abnormal production of hepcidin), and reduced intracellular uptake of iron have been reported as causes of anemia in patients with HF. 31, 32 In this study, we examined CPB time and LVAD surgery time in the prediction model of early post-LVAD RHF. Both parameters are significantly associated with the incidence of early post-LVAD RHF; however, a CPB time >100 minutes remained significant in the final model. It is associated with a 2-fold increase in the incidence of early post-LVAD RHF, but it did not improve much the AUC of the composite score. 
Clinical Implications
In this study, RHF was associated with increased early and late mortality. Most common causes of death were multiorgan failure, sepsis and cerebrovascular accidents. Patients with RHF died more often as a result of multiorgan failure and sepsis. Those patients have severe systemic congestion and tissue hypoperfusion from underfilling of the LVAD. Moreover, patients with RHF had a longer ICU stay. It has been reported that ≈50% of ICU patients had a nosocomial infection and are therefore at a high risk for sepsis. 33 Furthermore, intestinal source of infection is a known source of sepsis in patients with multiorgan failure in the ICU as a result of translocation of gut flora into bloodstream.
In this study, the composite 5-point score predicts early post-LVAD RHF, with graded risk for both RHF and death seen with higher scores. The score is simple, validated, and composed of widely available and clinically relevant variables derived from a multivariate logistic regression analysis. In contrast, the more complex recently published machine prediction bayesian models 34 from the INTERMACS database consisted of 33 to 34 preoperative variables.
Our model variable selection was based on biological plausibility and knowledge of experts in the field to avoid redundancy in the model and unexplained or unexpected predictors. This risk score includes intuitive predictors that are known to be relevant in the pathophysiology of early post-LVAD RHF and its associated mortality. Furthermore, the final model of the EUROMACS-RHF risk score was validated in a separate validation cohort.
This novel scoring system may provide clinicians with opportunity for tailored risk decision making before, during, or early after LVAD surgery. A patient with a high risk score may require perioperative optimization of RV support, biventricular assist device, or total heart support. Optimization of RV support could be achieved via reduction of preload, afterload, and RV contractility support. Aggressive diuresis, early use of pulmonary vasodilators such as NO, phosphodiesterase type 5 inhibitors, or early RV mechanical support may be indicated. Furthermore, measures such as tricuspid valve repair could be considered. Those patients would benefit from early recognition in terms of not only less need for prolonged ICU stay but also, more important, better survival. However, those corrective measures remain speculative and should be tested in some prospective randomized trials to prove their usefulness.
Limitations
Caution should be taken in general against using solely a risk model for clinical decision making without prospective validation in randomized clinical trials. There are several limitations that should be acknowledged in this study. First, a validation ROC of 0.67 of this risk score is not ideal. It could be due to the fact that only very few patients were assigned to some high scores. The score could perform better in a larger population in which more patients are represented in all score levels. Another limitation is the semiquantitative assessment of RV function on echocardiography. A quantitative and preferably advanced RV assessment such strain analysis could improve the score performance. On the other hand, the widely used scores, also simple, such as CHADS 2 -VASC 35 and even Pooled Cohort equations 36 are not different from this score. Furthermore, it may not be appropriate to generalize our findings to other types of VAD not included in the present analysis. However, the 3 LVADs in this study represent the mainstream LVADs used worldwide. An important limitation of this study is the retrospective analysis of the EUROMACS database. However, data on MCS devices are derived largely from registry databases. A prospective randomized study such as in patients with cardiogenic shock on multiple inotropes, which had the highest weight among RHF predictors, is warranted to prove the predictive value of this risk score.
Furthermore, there are potential confounders that might not be accounted for here. In addition, potential mechanisms of RHF that take place exclusively after LVAD surgery such as an immediate increase in RV work to match the increase in LVAD flow are not considered. Missing data were present for many of our variables. However, we addressed this issue by using multiple imputations, and no variables were missing in >90% of cases. Medication dosages were not considered in the present model. Pharmacological interventions could alter many biological markers such as hepatic and renal functional biomarkers, thus affecting the meaning of those markers in a prediction model. Of note, only hemoglobin appeared in the final step of the EUROMACS-RHF risk model.
Conclusions
We developed and validated the EUROMACS-RHF risk score, a simple 5-item scoring system for the prediction of early RHF and RHF-associated mortality after continuous-flow LVAD implantation. The score identified high-risk patients in whom timely optimization or mechanical RV support may be considered to reduce RHF-related mortality and morbidity.
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